Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
Rani Therapeutics Holdings Stock
Rani Therapeutics Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Talat Imran
- Employees
- 70
- Market cap
- $48 M
- IPO
- 30/07/2021
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a…
Rani Therapeutics Holdings stock: price history
1D
-2.4%
1W
-11.5%
1M
-13.0%
6M
-12.4%
YTD
-45.7%
1Y
+56.5%
2Y
-63.7%
5Y
-96.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Rani Therapeutics Holdings
Analyst assessment of Rani Therapeutics Holdings
PRICE TARGET LOW
US$9.00
CONSENSUS
US$15.67
MEDIAN
US$10.00
PRICE TARGET HIGH
US$28.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 21/08/2026
Rani Therapeutics Holdings stock metrics
P/E
-2.72
P/B
3.5
EV/EBITDA
-1.46
RETURN ON EQUITY
-18.8%
NET MARGIN
-432.7%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.2%
FLOAT SHARES
47,135,891
AVG. DAILY VOLUME (30D)
549,911
Insider transactions (SEC)
Javadi Alireza
Imran Talat
IMRAN MIR A
Imran Talat
Imran Talat
Institutional holders
Comparable stocks
Frequently asked questions about Rani Therapeutics Holdings stock
What does Rani Therapeutics Holdings do?
Rani Therapeutics Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Talat Imran, the company employs around 70 people.
The IPO was on 30/07/2021; the stock trades on NASDAQ under the ticker RANI.
What do analysts say about Rani Therapeutics Holdings stock?
7 analysts rate the stock, the consensus is Buy (as of 21/08/2026).
The average price target is US$15.67, ranging from US$9.00 to US$28.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Rani Therapeutics Holdings report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Rani Therapeutics Holdings pay a dividend?
No, Rani Therapeutics Holdings currently does not pay a dividend.
Which stocks are comparable to Rani Therapeutics Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rani Therapeutics Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rani Therapeutics Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.